News

ImaginAb Inc. announced that it has signed a multi-year non-exclusive license agreement with AstraZeneca. Under the terms of the agreement, ImaginAb's CD8 ImmunoPET technology will…
Read More...

Altimmune, Inc., announced that it is launching a collaboration with the University of Alabama at Birmingham (UAB) on the development of its single-dose, intranasal COVID-19 vaccine,…
Read More...

Noveome Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing next-generation biologics for the promotion and restoration of cellular integrity of inflamed or…
Read More...

GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, announced it has been…
Read More...

Aptorum Group Limited, a biopharmaceutical company focused on the development of novel therapeutics for unmet needs including but not limited to infectious, orphan and metabolic disease…
Read More...

Cobra Biologics and the Karolinska Institutet announced they have been awarded €3million emergency funding by Horizon 2020 for research and development, and phase I clinical trial…
Read More...

Sorrento Therapeutics, Inc. announced it has entered into a research testing agreement with The University of Texas Medical Branch at Galveston for the preclinical testing of Sorrento’s…
Read More...

AstraZeneca’s Imfinzi (durvalumab) has been approved in the US as a 1st-line treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC) in combination with…
Read More...

Ryvu Therapeutics, a clinical-stage biopharmaceutical company developing novel small molecule therapies that address emerging targets in oncology, announced that the U.S. Food and Drug…
Read More...

AstraZeneca’s Lokelma (sodium zirconium cyclosilicate) has been approved in Japan for the treatment of patients with hyperkalaemia (elevated levels of potassium in the blood). The…
Read More...

Sartorius, a leading international partner of life science research and the biopharmaceutical industry, has supported CanSino Biologics Inc. (“CanSinoBIO”) and Maj. Gen. Chen Wei’s team…
Read More...

AstraZeneca will collaborate with Silence Therapeutics to discover, develop and commercialise small interfering RNA (siRNA) therapeutics for the treatment of Cardiovascular, Renal,…
Read More...

Sorrento Therapeutics, Inc. announced it has been working on a novel decoy cellular vaccine for COVID-19 (STI-6991) and is in active discussions with the FDA’s Center for Biologics…
Read More...

Forge Therapeutics, Inc. (Forge) announced that they have entered into a research collaboration and option agreement with Hoffmann-La Roche Ltd. (Roche) to license FG-LpxC LUNG, a novel…
Read More...

Grifols announces that it has entered into a formal collaboration with the United States Biomedical Advanced Research Development Authority (BARDA), the Food and Drug Administration…
Read More...

Debiopharm announced having entered into a worldwide, exclusive license & research agreement with 3B Pharmaceuticals (3BP), a German biotechnology firm, to further the development…
Read More...

Xencor, Inc. announced that it has entered into a technology license agreement with Vir Biotechnology, Inc., in which Vir will have non-exclusive access to Xencor’s Xtend Fc technology…
Read More...

Infinity Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for IPI-549 in combination with nivolumab (Opdivo) for the…
Read More...

Alvotech Hf and DKSH, a leading healthcare provider across 36 emerging countries in South-East Asia, announced that Alvotech Hf and DKSH have entered into an exclusive license…
Read More...

CytomX Therapeutics, Inc. and Astellas Pharma Inc. announced that they have entered into a strategic collaboration agreement focused on the discovery, research, development and…
Read More...